论文部分内容阅读
目的探讨还原型谷胱甘肽(GHS)治疗酒精性肝病(ALD)的临床疗效。方法 70例ALD患者随机分为治疗组和对照组。对照组给予常规治疗,治疗组给予常规治疗联合GHS治疗。治疗30d后评价临床疗效,观察治疗前后谷丙转氨酶(ALT)、谷草转氨酶(AST)、谷氨酞转移酶(GGT)和甘油三酯(TG)水平变化。结果治疗组临床疗效总有效率为94.3%,显著高于对照组(71.4%),两组比较差异有统计学意义(P<0.05);治疗后,两组ALT、AST、GGT、TG水平与治疗前比较均显著下降(P<0.05);且治疗组与对照组比较也显著下降(P<0.05)。结论GHS治疗ALD具有改善患者肝功能和降低血脂的作用。
Objective To investigate the clinical efficacy of reduced glutathione (GHS) in the treatment of alcoholic liver disease (ALD). Methods Seventy patients with ALD were randomly divided into treatment group and control group. The control group was given routine treatment, and the treatment group was given conventional treatment combined with GHS treatment. After 30 days of treatment, the clinical efficacy was evaluated. The levels of ALT, AST, GGT and triglyceride were observed before and after treatment. Results The total effective rate of the treatment group was 94.3%, significantly higher than that of the control group (71.4%), the difference was statistically significant (P <0.05); after treatment, the levels of ALT, AST, GGT, Compared with the control group, the treatment group and the control group also decreased significantly (P <0.05). Conclusion GHS treatment of ALD can improve liver function and reduce blood lipid in patients.